In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 251 to 275 of 437

TitleTypeExpected publication date
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]Technology appraisal guidanceTBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Technology appraisal guidanceTBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]Technology appraisal guidanceTBC
Nirogacestat for treating desmoid tumours [ID6453]Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Technology appraisal guidanceTBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Technology appraisal guidanceTBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]Technology appraisal guidanceTBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]Technology appraisal guidance
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidanceTBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Technology appraisal guidanceTBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519Technology appraisal guidance
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [ID6420]Technology appraisal guidance
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and managementNICE guideline
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitationInterventional procedures guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All